Consolidated Statements of Operations
   

(In thousands except per share amounts)
       
Years Ended December 31,
2000
1999
 1998
 
 
Net Revenue
$13,262,754 
$11,881,196 
$11,268,570 
Cost of goods sold
3,269,418 
3,022,556 
2,843,185 
Selling, general and administrative expenses
5,032,548 
4,388,265 
4,209,162 
Research and development expenses
1,687,889 
1,587,505 
1,475,862 
Interest expense, net
57,562 
213,866 
207,157 
Other income, net
(161,039)
(255,697)
(285,848)
Gains on sales of business and Immunex common stock
(2,061,204)
- 
(592,084)
Termination fee
(1,709,380)
- 
- 
Litigation charges
7,500,000 
4,750,000 
- 
Goodwill impairment
401,000 
- 
- 
Special charges
347,000 
82,000 
321,200 
Income (loss) from continuing operations before federal and foreign taxes
(1,101,040)
(1,907,299)
3,089,936 
Provision (benefit) for federal and foreign taxes
(200,000)
(700,056)
937,592 
Income (Loss) from Continuing Operations
(901,040)
(1,207,243)
2,152,344 
Discontinued operations:
 
  Income (loss) from operations of discontinued agricultural
    products business (including federal and foreign taxes of
    $57,289, $1,551 and $173,530 for 2000, 1999 and 1998,
    respectively)
103,346 
(19,878)
321,994 
  Loss on disposal of agricultural products business
    (including federal and foreign tax charges of $855,248)
(1,572,993)
-
- 
Income (Loss) from Discontinued Operations
(1,469,647)
(19,878)
321,994 
Net Income (Loss)
$(2,370,687)
$ (1,227,121)
$ 2,474,338 
Basic Earnings (Loss) per Share from Continuing Operations
$ (0.69)
$ (0.92)
$ 1.64 
Basic Earnings (Loss) per Share from Discontinued Operations
(1.12)
(0.02)
0.24 
Basic Earnings (Loss) per Share
$ (1.81)
$ (0.94)
$ 1.88 
Diluted Earnings (Loss) per Share from Continuing Operations
$ (0.69)
$ (0.92)
$ 1.61 
Diluted Earnings (Loss) per Share from Discontinued Operations
(1.12)
(0.02)
0.24 
Diluted Earnings (Loss) per Share
$ (1.81)
(0.94)
$ 1.85 


The accompanying notes are an integral part of these Consolidated Financial Statements.